Table 2.

Summary of treatment responses in the 1181 total patients and 1026 evaluable patients

Efficacy outcomes	Total (n = 1181, 100%) Evaluable (n = 1026, 100%)
	n (%) or [median]	95% CI
ORR	338 (28.6) [32.9]	(26.0, 31.2)
DCR	653 (55.3) [63.7]	(52.5, 58.1)
TTR (months)	2.3	(2.1, 2.5)
DOR (months)	13.1	(11.9, –)

Best response	Event, n	% (Total n = 1181)	% (Total n = 1023)
CR (Complete response)	9	0.7	0.9
PR (Partial response)	329	27.9	32.2
SD (Stable disease)	315	26.7	30.8
PD (Progressive disease)	373	31.6	36.5
N/A or N/E	155	13.1

ORR Objective response rate, DCR disease-control rate, TTR time-to-response, DOR duration of response, N/A not available, N/E non-evaluable